{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:13:56Z","timestamp":1786986836350,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clcc.2019.06.006","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T15:20:59Z","timestamp":1562080859000},"page":"192-199.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"Adam","family":"Cerise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan K.","family":"Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2019.06.006_bib1","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1158\/1078-0432.CCR-15-1623","article-title":"New life for immunotoxin cancer therapy","volume":"22","author":"Hassan","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.06.006_bib2","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2017-09-803072","article-title":"Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up","volume":"131","author":"Kreitman","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clcc.2019.06.006_bib3","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2017-02-749101","article-title":"Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia","volume":"130","author":"Wayne","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clcc.2019.06.006_bib4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clcc.2019.06.006_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.clcc.2019.06.006_bib6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","article-title":"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis","volume":"124","author":"Hassan","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clcc.2019.06.006_bib7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000478-200302000-00002","article-title":"Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura","volume":"27","author":"Miettinen","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clcc.2019.06.006_bib8","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ordonez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clcc.2019.06.006_bib9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"Chowdhury","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clcc.2019.06.006_bib10","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.06.006_bib11","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clcc.2019.06.006_bib12","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/1535-7163.MCT-14-0089-T","article-title":"In\u00a0vitro and in\u00a0vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer","volume":"13","author":"Hollevoet","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clcc.2019.06.006_bib13","doi-asserted-by":"crossref","first-page":"E3501","DOI":"10.1073\/pnas.1721780115","article-title":"Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity","volume":"115","author":"Wei","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clcc.2019.06.006_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijc.2910410221","article-title":"Biological characterization and oncogene expression in human colorectal carcinoma cell lines","volume":"41","author":"Trainer","year":"1988","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2019.06.006_bib15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0046-8177(03)00177-1","article-title":"Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas","volume":"34","author":"Frierson","year":"2003","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clcc.2019.06.006_bib16","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","article-title":"Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma","volume":"8","author":"Inaguma","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clcc.2019.06.006_bib17","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.1073\/pnas.1209292109","article-title":"Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes","volume":"109","author":"Liu","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clcc.2019.06.006_bib18","doi-asserted-by":"crossref","first-page":"10666","DOI":"10.1073\/pnas.1611481113","article-title":"Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis","volume":"113","author":"Liu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clcc.2019.06.006_bib19","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/0008-5472.CAN-09-2405","article-title":"A\u00a0flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clcc.2019.06.006_bib20","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-06-0346","article-title":"Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice","volume":"12","author":"Zhang","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.06.006_bib21","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1535-7163.MCT-15-0863","article-title":"Reduced shedding of surface mesothelin improves efficacy of mesothelin-targeting recombinant immunotoxins","volume":"15","author":"Awuah","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clcc.2019.06.006_bib22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.canlet.2015.09.007","article-title":"New avenues for improving pancreatic ductal adenocarcinoma (PDAC) treatment: selective stroma depletion combined with nano drug delivery","volume":"369","author":"Bhaw-Luximon","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clcc.2019.06.006_bib23","first-page":"2807","article-title":"Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in\u00a0vivo","volume":"32","author":"Nukatsuka","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2019.06.006_bib24","first-page":"1189","article-title":"Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin","volume":"5","author":"Zeghari-Squalli","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.06.006_bib25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.clcc.2019.06.006_bib26","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.3390\/ijms16035386","article-title":"Different apoptotic pathways activated by oxaliplatin in primary astrocytes vs. colo-rectal cancer cells","volume":"16","author":"Zanardelli","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clcc.2019.06.006_bib27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"Bharadwaj","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.clcc.2019.06.006_bib28","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.clcc.2019.06.006_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clcc.2019.06.006_bib30","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.06.006_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clcc.2019.06.006_bib32","doi-asserted-by":"crossref","first-page":"11694","DOI":"10.18632\/oncotarget.3429","article-title":"High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis","volume":"6","author":"Thomas","year":"2015","journal-title":"Oncotarget"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002819301768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002819301768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:05:37Z","timestamp":1761519937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002819301768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1533002819301768"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2019.06.006","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2019.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}